NCT07159074View on ClinicalTrials.gov

Repurposing Tilmanocept for Cardiac Sarcoidosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 31, 2026

Conditions
Cardiac Sarcoidosis
Interventions
DRUG

Tc 99m tilmanocept

150 mcg containing 10 mCi of Tc 99m tilmanocept will be administered through an IV route of injection. SPECT-CT imaging will then be performed.

Trial Locations (1)

27710

Duke University Hospital, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Foundation for Sarcoidosis Research

OTHER

lead

Duke University

OTHER

NCT07159074 - Repurposing Tilmanocept for Cardiac Sarcoidosis | Biotech Hunter | Biotech Hunter